Evidence map›Paper›PMID 40189783›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The striatum is an early, accurate indicator of amyloid burden using [

Max McLachlan, Brecca Bettcher, Andrew McVea, Alexandra DiFilippo, Matthew Zammit, Lisette LeMerise, Jeremy Rouanet, Julie Price, Dana Tudorascu, Charles Laymon and 16 more

Abstract readComparative Study
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Structural MRI across lifespan reveals differential thalamic trajectories in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Development of Molecular Neuropathology in Down Syndrome across the Lifespan.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  8. Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Article
  10. Article
  11. The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. The striatum is an early, accurate indicator of amyloid burden using [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  13. Article
  14. Longitudinal amyloid burden with combined [Imaging neuroscience (Cambridge, Mass.)
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Max McLachlanSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0003-1801-7233
Brecca BettcherSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Andrew McVeaSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alexandra DiFilippoSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Matthew ZammitSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Lisette LeMeriseSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jeremy RouanetSchool of Medicine, University of California, Irvine, California, USA.
Julie PriceMass General Research Institute, MGH, Harvard Medical School, Boston, Massachusetts, USA.
Dana TudorascuDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Charles LaymonDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
David KeatorSchool of Medicine, University of California, Irvine, California, USA.
Patrick LaoVagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Adam M BrickmanVagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Tim FryerUniversity of Cambridge, The Old Schools, Trinity Ln, Cambridge, TN, UK.
Sigan HartleySchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Beau M AncesDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
H Diana RosasMass General Research Institute, MGH, Harvard Medical School, Boston, Massachusetts, USA.
Sterling JohnsonSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Tobey BetthauserSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Charles K StoneSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Shahid ZamanUniversity of Cambridge, The Old Schools, Trinity Ln, Cambridge, TN, UK.
Benjamin HandenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Elizabeth HeadSchool of Medicine, University of California, Irvine, California, USA.
Mark MapstoneSchool of Medicine, University of California, Irvine, California, USA.
Bradley T ChristianSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Abc-Ds Investigators

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANCES, BEAU M · 2020 to 2025
$103.7M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI YASSA, MICHAEL A · 2000 to 2019
$37.0M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Mathew Mark Blurton-Jones · 2020 to 2026
$27.9M
Biomarkers of Alzheimer's Disease in Adults with Down SyndromeU01AG051412 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOTT, IRA T., SCHUPF, NICOLE · 2015 to 2019
$26.3M
DS-Connect (The Down Syndrome Registry)Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG072973NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS U01 AG051406NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054NIA NIH HHS U24 AG021886NICHD NIH HHS P50 HD105353NIH HHS P30 AG062421NIH HHS P30 AG062715NIH HHS P30 AG066468NIH HHS P30 AG066519NIH HHS P30 AG072973NIH HHS P50 AG005133NIH HHS P50 AG005681NIH HHS P50 AG008702NIH HHS P50 AG016573NIH HHS P50 HD105353NIH HHS U01 AG051406NIH HHS U01 AG051412NIH HHS U19 AG068054NIH HHS U24 AG021886
6 · The paper itself

Abstract

introductionAdults with Down syndrome demonstrate striatum-first amyloid accumulation with [

methodsLongitudinal PiB (n = 175 participants) and FBP (n = 92 participants) data from the Alzheimer Biomarkers Consortium-Down Syndrome (ABC-DS) were used to measure cortical and striatal binding. Generalized temporal models for cortical and striatal amyloid accumulation were created using the sampled iterative local approximation (SILA) method.

resultsPiB demonstrated greater striatal-to-cortical ratios than FBP. SILA analysis revealed striatal amyloid burden occurs 3.40 (2.39) years earlier than the cortex in PiB. There was no difference between the cortex and striatum in FBP. DISCUSSION: Among adults with Down syndrome, the striatum consistently accumulates amyloid earlier than the cortex when measured with PiB. This suggests the striatum is more sensitive to the onset of PiB PET-detectable amyloid in Down syndrome. HIGHLIGHTS: Striatal amyloid is detectable 3.4 years before the cortex using PiB PET in DS. Florbetapir PET does not detect early striatal amyloid accumulation in DS. White matter can be used as reference region in longitudinal florbetapir PET. SILA trajectory models can be used to compare regional estimates for age of onset.

Indexed as

AmyloidCorpus StriatumDown SyndromePositron-Emission TomographyAdultAniline CompoundsCarbon RadioisotopesCerebral CortexEthylene GlycolsFemaleHumansLongitudinal StudiesMaleMiddle AgedRadiopharmaceuticalsThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloidAniline CompoundsCarbon RadioisotopesEthylene GlycolsflorbetapirRadiopharmaceuticalsThiazolesAlzheimer's diseaseDown syndromeflorbetapirlongitudinalPET imagingPiBstriatum

Identifiers

PMID40189783
PMCPMC11972983

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.